Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 19435431.
- Also identified by DOI 10.1086/599224.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clostridium difficile infection (CDI) has become more refractory to standard therapy. We describe 4 patients with severe refractory CDI who were successfully treated with tigecycline. Symptoms improved within 1 week. No relapses were observed. This favorable outcome suggests that tigecycline might be a useful alternative for treating severe refractory CDI.
Medical subject headings
- Anti-Bacterial Agents
- Clostridioides difficile
- Enterocolitis, Pseudomembranous
- Minocycline